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Abstract
Background—Adequate relief of IBS symptoms (IBS-AR) has been used as a primary endpoint
in many randomized controlled trials of IBS and is considered by the Rome III Committee to be an
acceptable primary endpoint. However, controversy exists on whether baseline severity confounds
the effect of this treatment patient outcome.
Aims—In a randomized controlled treatment trial (1) to compare subjective report of IBS-AR to
global assessment of improvement (IBS-GAI), change in IBS symptom severity scale (IBS-SSS) and
IBS Quality of Life (IBS-QOL); (2) to explore whether initial IBS symptom severity influences the
sensitivity of these outcome measures; (3) to determine whether psychological symptoms influence
the sensitivity of these measures.
Methods—289 adult IBS patients were recruited to a treatment trial. Baseline IBS-SSS scores were
used to classify IBS severity as mild (<150), moderate (150-300), or severe (>300). Questionnaires
were completed at baseline and after 3 weeks of treatment with sham acupuncture or waitlist control.
Results—IBS baseline severity significantly affected the proportion of patients who reported IBS-
AR at 3 weeks (mild, 70%; moderate, 49.7%; severe, 38.8%) (p<0.05). However, once the patients
who reported IBS-AR at baseline (28.0%) were excluded from the analysis, baseline severity no
longer affected the proportion of patients reporting IBS-AR. Baseline severity did not have a
significant of effect patients reporting moderate or significant improvement on the IBS-GAI (mild,
30%; moderate, 25.3%; severe, 18.8%) (p=NS). Psychological symptoms had no significant
correlations with responders after adjusting for baseline severity.
Conclusions—These data suggest that IBS-AR as an endpoint is confounded with initial IBS
symptom severity as measured by baseline reporting of adequate relief. The confounding effects of
adequate relief can be eliminated if patients who report adequate relief at screening are excluded
from study participation.
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Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by
chronic or recurrent abdominal pain or discomfort, usually in the lower abdomen, which is
associated with disturbed bowel function and feelings of abdominal distention and bloatedness
(1). The abdominal discomfort and/or pain associated with IBS is usually relieved by defecation
(2,3). There are other symptom features that can be associated with IBS. This makes it difficult
to gauge treatment response or select a primary outcome primarily by improvement of a specific
symptom (4,5).
Furthermore, in contrast to conditions like ulcerative colitis or Crohn's disease where treatment
response can be gauged by reduction in mucosal inflammation, there are no biological markers
in IBS, making treatment response completely subjective. Patient reported outcome measures
that assess global improvement in IBS capture the range of symptoms experienced by a patient.
The Food and Drug Administration (FDA) has accepted a patient reported outcome of global
improvement in IBS as a primary endpoint (6). One of the most commonly used global outcome
measures in IBS clinical trials asks the patient weekly if they have experienced adequate relief
(AR) of their IBS symptoms or pain (i.e., “In the last seven days, have you had adequate (or
satisfactory) relief of your IBS symptoms?”).
The endpoint of IBS-AR has been shown to be a clinically and statistically relevant benefit in
therapeutic IBS trials with alosetron (7-9), cilansetron (10-12) and tegaserod (13-15). These
studies suggest that as an endpoint IBS-AR is responsive, reproducible, and moves in the same
direction as other meaningful measures (16). Furthermore, the Rome III committees identified
IBS-AR as the current standard of assessment for clinical trials noting that validation of this
endpoint is needed (17).
There have been some criticisms of the use of adequate or satisfactory relief as a patient reported
outcome. In a 6 month study of IBS patients receiving standard medical care in an HMO setting,
Whitehead et al. (18) found that at baseline the patients with the mildest severity reported the
highest proportion of satisfactory relief when asked the measure once, 6 months later. These
findings suggest that satisfactory relief (or by implication adequate relief) is confounded by
IBS symptom severity and correlated poorly with the amount of symptom improvement.
However, it may be difficult to extrapolate this finding to a clinical trial situation since it was
based on data obtained from a usual care cohort of an HMO. An additional caveat to such an
extrapolation is that patients not reporting symptoms were considered to have satisfactory
relief. Therefore it is possible that expectation of satisfactory relief may be different in a usual
care situation as compared to a true clinical trial. Finally, it is possible that a larger proportion
of subjects in a usual care situation might report satisfactory or adequate relief at baseline than
in a clinical trial, since the former are not specifically seeking to be enrolled in a clinical trial.
Accordingly, as noted by the authors there is a pressing need to re-evaluate these data through
use of a prospective clinical trial.
The aims of this study of a randomized clinical trial were: (1) To compare subjective report of
adequate relief (IBS-AR) to global assessment of improvement (IBS-GAI), change in IBS
symptom severity scale (IBS-SSS) and IBS Quality of Life (IBS-QOL) in a randomized clinical
trial (RCT); (2) To explore whether and how initial IBS symptom severity may influence the
sensitivity of these outcome measures; (3) To determine whether psychological symptoms
influence the sensitivity of these measures.
Methods
In this single center, single-blind, randomized, control trial, 289 IBS-patients were randomized
to Waitlist or Sham Acupuncture with either a neutral or an “augmented” patient-practitioner
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interaction. The main study had 262 patients; a nested study that included qualitative interviews
had an additional 27 patients randomized to each arm. For ethical reasons patients were
subsequently re-randomized to receive sham or verum acupuncture for an additional 3 weeks.
The rationale for this design was to assess the effect of placebo response and patient-practitioner
interaction in IBS. The results of the main study will be reported elsewhere. For the purposes
of this study patient assessments at baseline and 3 weeks were used and all subjects were
combined into one group for analysis.
Subjects
Participants were recruited from advertisements in media, fliers and referrals from health
professionals and were all at least 18 years old and met the Rome II criteria for IBS (19).
Patients were excluded if they had such unexplained findings as weight loss >10% body weight,
fever, blood in stools, family history of colon cancer, or inflammatory bowel disease. The
diagnosis of IBS was based on typical symptoms (20,21) and confirmed by a board certified
gastroenterologist experienced in functional bowel disorders (AJL). Participants were allowed
to continue IBS medications (e.g., fiber, anti-spasmodics, loperamide) as long as they had been
on stable doses for at least 30 days prior to entering the study and agreed not to change
medications or dosages during the trial. The Institutional Review Boards at the Beth Israel
Deaconess Medical Center and Harvard Medical School approved the design.
Questionnaires
The questionnaires at baseline and 3 week follow-up included the following: (1) The IBS
Global Assessment of Improvement Scale (IBS-GAI) (13); (2) The IBS Symptom Severity
Scale (IBS-SSS) (22); (3) A binary response question, Adequate Relief (IBS-AR), assessing
whether the patient had obtained adequate relief of bowel symptoms during the preceding 7
days (7,9,10); (4) IBS Quality of Life Scale (IBS-QOL) (23); (5) NEO Inventory, of which the
Neuroticism scale of the multi-scale NEO Inventory was used to assess personality dysfunction
relating to resiliency in the face of stress (24); (6) Beck Depression Inventory (BDI) which
assessed symptoms of depression (25).
IBS Global Assessment of Improvement Scale (IBS-GAI)—IBS Global Improvement
Scale (IBS-GAI) asks participants: “Compared to the way you felt before you entered the study,
have your IBS symptoms over the past 7 days been: 1) “Substantially Worse”, 2) “Moderately
Worse”, 3)“Slightly Worse”, 4) “No Change”, 5)“Slightly Improved”, 6)“Moderately
Improved” or 7) “Substantially Improved” (26,27). (26,27)(26,27)
IBS Symptom Severity Scale—The IBS Symptom Severity Scale (IBS-SSS) contains five
questions that measure, on a 100-point VAS the severity of abdominal pain, the frequency of
abdominal pain, the severity of abdominal distention, dissatisfaction with bowel habits, and
interference with quality of life (22). All five components contribute to the score equally
yielding a theoretical range of 0-500, with a higher score indicating worse condition. Previous
studies have established that scores below 175 represent mild IBS symptoms, 175–300
represents moderate severity, and scores above 300 represent severe IBS (22). The total severity
score on the IBS-SSS was treated as the gold standard measure of IBS severity. In the study
by Francis et al. (22) a decrease of 50 points correlated with improvement in clinical symptoms.
IBS-Adequate Relief—IBS-Adequate Relief (IBS-AR) is a dichotomous single item that
asks participants “Over the past week have you had adequate relief of your IBS
symptoms?” (6,16).
IBS-Quality of Life—The IBS-Quality of Life (IBS-QOL) is a 34-item measure assessing
the degree to which IBS interferes with patient quality of life. Each item is rated on a 5-point
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Likert scale, thus yielding a total score that has a theoretical range of 34 to 170, with higher
scores indicating worse QOL (23,28).
Definition of a Responder—For this analysis we identified those who responded to the
intervention according to the four main outcomes described above. As such, four different
responder definitions were compared: (1) IBS-AR, where a responder was defined as a patient
who reported at the 3-week follow-up that for the last 7 days they had experienced “adequate
relief” (who responded “yes”); (2) IBS-GAI, where a responder was defined as a patient who
responded that, compared to 3 weeks ago, their symptoms were either “moderately improved”
or “substantially improved”; (3) change in total IBS-SSS score from enrollment to 3 weeks
follow-up, where a responder was defined as a patient whose overall symptom severity on the
IBS-SSS changed ≥ 50 points, and (4) change in IBS-QOL from enrollment to 3 weeks follow-
up, where a responder was defined as a clinically meaningful change of ≥ 10 points in this
measure.
Statistical Analysis
All data were analyzed using SAS (Version 6.12). To address aim 1 (correlation among
outcome measures), the nonparametric correlation coefficient, Kendall's tau-b, was computed.
To address aim 2, χ2 was used to test whether the responder rates differed between patients
classified as having mild, moderate and severe IBS symptoms at enrollment. For the continuous
outcome variables (i.e., more than 50% reduction of IBS-SSS at week three compared with
that at enrollment, change in total IBS symptom severity score from enrollment to 3 weeks
follow-up, and change in IBS-QOL from enrollment to 3 weeks follow-up), analysis of variance
was used to compare the IBS symptom severity groups. To address aim 3 (determine whether
psychological status influenced outcome measures), a t-test was used to compare patients
reporting adequate relief to no adequate relief. For other outcome measures (i.e., IBS-GAI,
change in IBS-SSS, and change in IBS-QOL score), Kendall's tau-b was computed.
Results
Patient Characteristics
Between December 2003 and February 2006, 350 prospective participants were screened, and
289 were enrolled into the study. Seventy-five percent of the patients were female, and 88%
were white. The mean age was 38.4 (range 18.8 – 76.4, s.d. 14.7 yr). Ninety-seven percent
graduated from high school and 80% were employed. IBS subtypes were as follows: 50% IBS-
Mixed, 28% IBS-Diarrhea and 23% IBS-Constipation. Most patients (94%) had IBS for more
than 1 year. At baseline, IBS-SSS was used to assess symptom severity; 23 (8%) had mild,
170 (59%) had moderate, and 96 (33%) had severe symptoms. No statistically significant
differences existed between these three symptom severity groups with regard to age, education,
pain scores, subtype of IBS, individual gastroenterology symptoms and psychosocial status.
Correlations among Responder Definitions
At week 3, there was a significant, although modest, correlation between the 4 endpoints used
in this study (Table 1).
Effects of Baseline Severity on Response to Treatment
Responder rates differed between patients classified as having mild, moderate and severe IBS
symptoms at baseline. Table 2 demonstrates the effects of IBS symptom severity at baseline
and the response to outcome measures at 3 week follow-up. Patients with mild IBS symptoms
were significantly more likely to be a responder for IBS-AR (70%) than were patients with
moderate (49.7%) or severe (38.8%) symptom severity. Similar results were seen when a
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responder was defined in terms of IBS-GAI: patients with moderate and severe IBS symptoms
at baseline were less likely to report that they were moderately or substantially better (moderate
(25.3)% and severe (18.8%)) compared to mild IBS symptoms (30%). In contrast, change in
IBS-SSS at week 3 was least in patients with mild IBS (20.3%) and greatest in patients with
severe IBS (83.7%). Change in IBS-QOL did not correlate with IBS severity. These results are
graphically depicted in Figure 1.
Comparison of Adequate Relief Responder and non-Responders
Patients who were responders to IBS-AR at week 3 when compared to non-responders clearly
had better health status and milder symptoms at that point as evidenced by the greater
improvement in IBS-SSS subscales for pain, bowel habit, interference with daily activities and
greater improvement in the total score of the IBS-SSS at week 3 as compared to patients who
were not IBS-AR responders. Therefore, adequate relief was seen to correlate well with
improvements in symptoms and other clinical parameters thus providing concurrent validity
for this responder definition (Table 3).
Effect of Baseline Reports of Relief
At the baseline visit participants were asked whether they had experienced adequate relief of
symptoms over the past week, in this case prior to entry into the study. As seen in Table 4,
IBS-AR at baseline was answered ‘yes’ by 39% of patients with mild symptom severity, 36.5%
with moderate symptom severity and only 10.4% of patients with severe symptom severity.
When patients who reported AR at baseline were removed, the discordance between adequate
relief being associated with less change in IBS-SSS as previously shown in Figure 1 was no
longer present. Thus severity of IBS no longer related inversely to the proportion with AR at
3 weeks (Figure 2). In contrast change in IBS-SSS improved more significantly in patients
severe IBS symptoms (p=0.035).
The 4 possible combinations of IBS-AR responses were also compared at baseline and week
3 with change in IBS-SSS (Table 5). Patients who did not have AR at baseline but reported
AR at week 3 had the greatest change in IBS-SSS (104.44) relative to those who did not report
AR at baseline or at week 3 (32.5; p>0.0001) or others who reported adequate relief at baseline
whether or not they had adequate relief at 3 weeks. This data confirms the importance of the
assessment of adequate relief at baseline in order to eliminate them from the treatment trial.
When patients with baseline adequate relief were eliminated from the analysis, baseline
symptom severity had no effect on endpoint adequate relief at week 3 (results not shown).
Effects of Psychological Symptoms on the Responder Rate
There were no significant differences between the responders in NEO and Beck questionnaires
from baseline to 3 weeks. Psychological symptoms did not correlate with responder status
(Table 6).
Discussion
Assessment of improvement in IBS clinical trials continues to evolve. Patient reported
assessment of adequate relief of IBS symptoms has been used as a primary endpoint in a number
of treatment trials and has been shown to be responsive to change, reproducible and correlate
with bowel symptoms. However, a recent study by Whitehead and colleagues (18) performed
in a usual care HMO found that patients with milder symptoms at baseline were more likely
to report satisfactory relief than patients with moderate or severe symptoms. This finding might
limit the value of global patient reported outcomes since baseline severity appears to confound
their validity as gauges of treatment response. Whitehead et al. recommended that similar data
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be obtained via prospective assessment in a treatment trial. This seemed logical since the
expectation for improvement in symptoms might be greater for patients entering a treatment
trial compared to patients in a usual care situation. Furthermore, it is possible that patients seen
in a usual care setting might report satisfactory relief at baseline since they are not a seeking
to meet severity criteria for enrollment in a treatment trial.
Similar to the study by Whitehead and colleagues (18) we found that patients with milder IBS
symptoms at baseline were more likely to report adequate relief during a treatment trial. It
should be noted that other studies have not found such an association (29,30). However, we
also found that a significant proportion of patients reported adequate relief during their baseline
assessment. When those patients were removed from the analysis there was no longer an inverse
relationship of adequate relief with baseline severity. Because of this, we believe that patients
who report adequate relief at baseline should not be considered eligible for a treatment trial.
Removing patients with adequate relief at baseline addresses the issues raised by Whitehead
and colleagues (18) and strengthens the validity of adequate relief as a primary patient reported
outcome in IBS clinical trials.
Our study highlights the fact that patient reported adequate relief of symptoms is a
multidimensional outcome that is influenced by a number of factors, including coping
mechanisms and psychological status, which may not directly related to symptom severity.
Thus patients may even have severe symptoms, yet the perception of adequate relief may be
influenced in the positive direction by modifying factors including coping and adjustment to
chronic illness. Notably, baseline IBS-QOL mirrored the severity of the symptoms as measured
by IBS-SSS, highlighting the importance of quality of life in patient assessments of global
severity.
This study has several limitations. First, this treatment trial was designed to assess the effects
of acupuncture and practitioner-patient relationship on IBS and did not employ a
pharmacological agent, which may have influenced patient expectations. Second, the study
cohort consisted of relatively small number of patients reporting mild symptoms. Future
research evaluating study endpoints should include a greater number of these patients. Third,
our study was only 3 weeks in duration and we assessed adequate relief only at baseline and
at 3 weeks. However, this observation must be balanced by our trial data which shows clinically
meaningful responses. Therefore, future studies assessing adequate relief as an endpoint should
include additional assessment points and should be of longer duration (i.e., weekly assessments
over a 12 week intervention).
In conclusion, our study demonstrates that as an endpoint in an IBS treatment trial adequate
relief is confounded by baseline symptom severity. However, when patients who report
adequate relief at baseline are removed from analysis baseline severity no longer confounds
response to adequate relief. Based on the results of our study we recommend that if adequate
relief is going to be used as a primary endpoint that patients be tested for this at baseline and
if they report adequate relief they should not enter into the study.
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Figure 1. Proportion of IBS responders according the severity of symptoms
Proportion reporting adequate relief and IBS-GAI is lowest in patients with severe at baseline,
but the magnitude of symptom improvement is greatest in patients with severe IBS. No
correlation was found in improvement IBS-QOL and severity of symptoms.
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Figure 2. Change in Adequate Relief and improvement in IBSSS*
* Baseline to 3 weeks - p=0.035
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Table 1
Correlations among outcome measures at week 3
IBS-GAI >50% Reduction IBS-SSS Change in IBS-SSS Change in IBS-QOL
Adequate relief 0.42 0.39 0.35 0.22
IBS-GAI 0.41 0.39 0.15*
>50% Reduction IBS-SSS 0.85 0.19
Change in IBS-SSS 0.19
All correlations (Kendall's tau-b) in table were significant at p<0.001 (except *p<0.01)
Am J Gastroenterol. Author manuscript; available in PMC 2009 July 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Passos et al. Page 12
Ta
bl
e 
2
E
ffe
ct
s o
f I
B
S-
SS
S 
on
 th
e 
m
ag
ni
tu
de
 o
f s
ym
pt
om
 r
ed
uc
tio
n 
at
 w
ee
k 
3
B
as
el
in
e
IB
S-
A
R
IB
S-
G
A
I
>5
0%
 I 
R
ed
uc
tio
n 
B
S-
SS
S
C
ha
ng
e 
in
 IB
S-
SS
S
C
ha
ng
e 
in
 IB
S-
Q
O
L
Se
ve
ri
ty
R
es
po
nd
er
R
es
po
nd
er
L
ev
el
N
R
at
e 
(%
)*
C
I
R
at
e
C
I
M
ea
n
C
I
M
ea
n†
C
I
M
ea
n
C
I
M
ild
23
70
.0
49
.4
, 9
0.
6
30
.0
9.
4,
 5
0.
6
12
.5
5
-4
.1
2,
 2
9.
23
20
.2
5
-5
.1
8,
 4
5.
68
8.
95
5.
17
, 1
2.
74
M
od
er
at
e
17
0
49
.7
41
.6
, 5
7.
7
25
.3
18
.3
, 3
2.
3
21
.6
1
17
.0
1,
 2
6.
22
52
.2
8
41
.0
7,
 6
3.
49
7.
93
5.
52
, 1
0.
34
Se
ve
re
96
38
.8
28
.0
, 4
9.
5
18
.8
10
.1
, 2
7.
4
22
.9
9
17
.6
4,
 2
8.
33
83
.7
3
63
.8
2,
 1
03
.6
3
10
.6
6
6.
64
, 1
4.
67
To
ta
l
28
9
47
.8
41
.6
, 5
4.
0
23
.6
18
.3
, 2
8.
9
21
.3
4
17
.8
8,
 2
4.
80
59
.9
4
50
.2
7,
 6
9.
61
8.
89
6.
94
, 1
0.
85
* D
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
ps
 w
as
 si
gn
ifi
ca
nt
 a
t p
<0
.0
5
† p
<0
.0
01
, a
nd
 a
ll 
ot
he
rs
 a
t p
>0
.0
5
Am J Gastroenterol. Author manuscript; available in PMC 2009 July 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Passos et al. Page 13
Table 3
Comparison of Responders to Non-responders on IBS-AR
No Adequate Relief
(n=130)
Adequate Relief
(n=119)
Mean CI Mean CI
IBS-SSS at 3 weeks FU (0-300 scale) 251.8 237.6, 266.1 168.5 155.0, 182.0
 Pain rating (0-100) 32.3 27.8, 36.8 19.7 15.9, 23.4
 Pain days in last 10 (0-10) 5.0 4.4, 5.6 3.4 2.9, 3.8
 Distention rating (0-100) 36.6 31.3, 41.8 21.4 17.3, 25.4
 Dissatisfaction w/Bowel Habits (0-100) 73.5 70.2, 76.7 50.7 47.2, 54.3
 Interfere w/Daily activities (0-100) 59.0 55.6, 62.3 43.3 39.6, 47.0
Change in IBS-SSS 28.0 16.3, 39.7 94.2 80.6, 107.7
IBS-QOL at week 3 (0-100)* 78.4 74.2, 82.5 71.7 67.4, 76.0
Change in IBS-QOL 4.9 2.8, 7.1 13.7 10.5, 17.0
IBS-SSS at baseline (0-500 scale)† 279.8 267.8, 291.8 262.6 249.7, 275.6
IBS-QOL at baseline (0-100 scale) † 83.3 79.1, 87.5 85.2 80.4, 90.1
†
Comparison significant at P>0.05
*
at P<0.05, and other comparisons significant at P<0.001.
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Table 5
Change in IBS-AR at baseline and week 3
IBS-AR Response at Baseline and week 3
No-Yes
N=70
Yes-Yes
N=48
Yes-No
N=22
No-No
N=108
Change in IBS-SSS
(mean ± S.D.) 85.3 ± 38 60.1 ± 37 35.9 ± 32 19.7 ± 16
Difference between groups was significant at P<0.0001
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Table 6
NEO and BECK correlation with responders: coefficient of correlation
IBS-AR IBS-GAI Change in IBS-SSS Change in IBS-QOL
Neuroticism 0.6659 0.7813 0.9687
Extraversion 0.2993 0.4223 0.1025
Beck Anxiety 0.9532 0.5895 0.8187 0.6603
Beck Depression 0.7804 0.8286 0.4055 0.1924
Proportion reporting adequate relief and IBS-GAI is lowest in patients with severe at baseline, but the magnitude of symptom improvement is greatest in
patients with severe IBS. No correlation was found in improvement IBS-QOL and severity of symptoms.
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